Baltimore doctors sued for excessive stent surgeries; Ariosa inks Dx distribution deal;

 @FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev

 @MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce

 @DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce

> Ariosa Diagnostics has signed a deal to distribute Harmony, its prenatal test for trisomy 21, in the U.K. News (reg. req.)

> A number of doctors at St. Joseph Medical Center in metro Baltimore are being sued for performing heart stent procedures in hundreds of patients who didn't need them. Story

> BioInspire, an Illinois medical device startup incubator, has fostered 5 nascent device companies, and its efforts impressed former Mexican President Vicente Fox during his recent visit. Article

> LGTmedical is developing a platform that would allow vital-sign monitors to connect to smartphones through audio inputs. More

> Pennsylvania's CD Diagnostics, a developer of diagnostic tests for joint pain, has completed its purchase of Citrano Medical Laboratories. Release

> Gore has enrolled the first patients in a pivotal trial of its Gore Septal Occluder, designed to treat atrial septal defect. Release

> The Economic Times of India explores how med device and med-tech startups launched there are advancing onto the global stage. Story

Biotech News

 @FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech

 @JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce

> Novo's long-acting insulin degludec takes big step to megamarket status. Story

> Wanted: Premier hepatitis C drug developer to partner with Vertex. Article

> U.K.'s Redx blueprints big R&D spinoff funded by government grant. News

Pharma News

@FiercePharma: Generics makers need to change their spots--and learn marketing--to sell biosimilars, Actavis, CEO says. More | Follow @FiercePharma

> GSK CEO remains 'a huge bull on India.' Story

> EMA committee shoots down Vivus diet pill. Article

> Actavis CEO: Biosims market will be tough to crack. News